

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



GB 2292144A

(12) UK Patent Application (19) GB (11) 2 292 144 (13) A

(43) Date of A Publication 14.02.1998

(21) Application No 9515775.6

(22) Date of Filing 01.08.1995

(30) Priority Data

(31) 9415997

(32) 08.08.1994

(33) GB

(71) Applicant(s)

Merck Sharp & Dohme Limited

(Incorporated in the United Kingdom)

Hertford Road, HODDESDON, Hertfordshire,
EN11 9BU, United Kingdom

(72) Inventor(s)

Richard Thomas Lewis
Angus Murray Macleod

(74) Agent and/or Address for Service

I J Hiscock

Merck & Co. Inc, European Patent Department,
Terlings Park, Eastwick Road, HARLOW, Essex,
CM20 2QR, United Kingdom(51) INT CL⁶

C07D 401/08, A61K 31/445

(52) UK CL (Edition O)

C2C CAA CQT C1343 C1532 C213 C215 C22Y C220
C226 C248 C25Y C250 C251 C28X C30Y C351 C355
C36Y C364 C398 C397 C482 C813 C825 C855 C872
C899 C80Y C800 C802
U1S S1313 S1318 S1321 S2415 S2416 S2417 S2418

(56) Documents Cited


WO 93/14084 A

(58) Field of Search

UK CL (Edition N) C2C CQN CQT CRE
INT CL⁶ C07D
Online: CASONLINE

(54) Piperidine derivatives and their use as therapeutic agents

(57) Compounds of the formula (I):



wherein


Q represents a phenyl group substituted by one or more halo, or naphthyl, indolyl, benzthiophenyl, benzofuranyl, benzyl or fluorenyl, each of which is optionally substituted;

R¹ represents H, OH, C₁₋₆alkoxy or phenyloxy;R² represents H, C₁₋₆alkyl or C₂₋₆alkenyl;

Z represents a group selected from



, or

where one of X and Y is H and the other is hydroxy or C₁₋₆alkoxy, or X and Y together form a group =O or =NOR⁵ where R⁵ is H or C₁₋₆alkyl;R³ represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl C₁₋₄alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b independently represent H, C₁₋₆alkyl, phenyl or trifluoromethyl;R⁴ represents H or C₁₋₆alkyl;

the dotted line represents an optional covalent bond;

(57) continued overleaf

GB 2 292 144 A

(57) cont

Ar represents phenyl optionally substituted by 1 or 2 groups selected from C₁₋₆alkyl C₁₋₆alkoxy, halo or trifluoromethyl; and

n represents 0, 1 or 2;

and pharmaceutically acceptable salts or prodrugs thereof,

are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia.

PIPERIDINE DERIVATIVES AND THEIR USE
AS THERAPEUTIC AGENTS

5 This invention relates to a class of heterocyclic compounds, which
are useful as tachykinin receptor antagonists.

 The tachykinins are a group of naturally occurring peptides found
widely distributed throughout mammalian tissues, both within the central
nervous system and in peripheral nervous and circulatory systems.

10 The tachykinins are distinguished by a conserved carboxyl-terminal
sequence:



 At present, there are three known mammalian tachykinins referred
to as substance P, neurokinin A (NKA, substance K, neuromedin L) and
neurokinin B (NKB, neuromedin K) (for review see J.E. Maggio, *Peptides*
15 (1985) 6(suppl. 3), 237-242). The current nomenclature designates the
three tachykinin receptors mediating the biological actions of substance P,
NKA and NKB as the NK₁, NK₂ and NK₃ receptors, respectively.

 Evidence for the usefulness of tachykinin receptor antagonists in
pain, headache, especially migraine, Alzheimer's disease, multiple
20 sclerosis, attenuation of morphine withdrawal, cardiovascular changes,
oedema, such as oedema caused by thermal injury, chronic inflammatory
diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity
and other respiratory diseases including allergic rhinitis, inflammatory
diseases of the gut including ulcerative colitis and Crohn's disease, ocular
25 injury and ocular inflammatory diseases, proliferative vitreoretinopathy,
irritable bowel syndrome and disorders of bladder function including
cystitis and bladder detruser hyper-reflexia is reviewed in "Tachykinin
Receptors and Tachykinin Receptor Antagonists", C.A. Maggi, R.
Patacchini, P. Rovero and A. Giachetti, *J. Auton. Pharmacol.* (1993) 13,
30 23-93.

For instance, substance P is believed *inter alia* to be involved in the neurotransmission of pain sensations [Otsuka *et al*, "Role of Substance P as a Sensory Transmitter in Spinal Cord and Sympathetic Ganglia" in 1982 Substance P in the Nervous System, Ciba Foundation Symposium 91, 13-34 (published by Pitman) and Otsuka and Yanagisawa, "Does
5 Substance P Act as a Pain Transmitter?" TIPS (1987) 8, 506-510], specifically in the transmission of pain in migraine (B.E.B. Sandberg *et al*, *J. Med. Chem.*, (1982) 25, 1009) and in arthritis [Levine *et al* in *Science* (1984) 226, 547-549]. Tachykinins have also been implicated in
10 gastrointestinal (GI) disorders and diseases of the GI tract such as inflammatory bowel disease [Mantyh *et al* in *Neuroscience* (1988) 25(3), 817-37 and D. Regoli in "Trends in Cluster Headache" Ed. Sicuteri *et al* Elsevier Scientific Publishers, Amsterdam (1987) page 85)] and emesis [F. D. Tattersall *et al*, *Eur. J. Pharmacol.*, (1993) 250, R5-R6]. It is also
15 hypothesised that there is a neurogenic mechanism for arthritis in which substance P may play a role [Kidd *et al* "A Neurogenic Mechanism for Symmetrical Arthritis" in *The Lancet*, 11 November 1989 and Grönblad *et al*, "Neuropeptides in Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis" in *J. Rheumatol.* (1988) 15(12), 1807-10]. Therefore,
20 substance P is believed to be involved in the inflammatory response in diseases such as rheumatoid arthritis and osteoarthritis, and fibrositis [O'Byrne *et al*, *Arthritis and Rheumatism* (1990) 33, 1023-8]. Other disease areas where tachykinin antagonists are believed to be useful are allergic conditions [Hamelet *et al*, *Can. J. Pharmacol. Physiol.* (1988) 66,
25 1361-7], immunoregulation [Lotz *et al*, *Science* (1988) 241, 1218-21 and Kimball *et al*, *J. Immunol.* (1988) 141(10), 3564-9] vasodilation, bronchospasm, reflex or neuronal control of the viscera [Mantyh *et al*, *PNAS* (1988) 85, 3235-9] and, possibly by arresting or slowing β -amyloid-mediated neurodegenerative changes [Yankner *et al*, *Science* (1990) 250,


279-82] in senile dementia of the Alzheimer type, Alzheimer's disease and Down's Syndrome.

Tachykinin antagonists may also be useful in the treatment of small cell carcinomas, in particular small cell lung cancer (SCLC) [Langdon *et al*, *Cancer Research* (1992) 52, 4554-7].

Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis [J. Lubner-Narod *et al*, poster C.I.N.P. XVIIIth Congress, 28th June-2nd July 1992], and in disorders of bladder function such as bladder detrusor hyper-reflexia (*Lancet*, 16th May 1992, 1239).

It has furthermore been suggested that tachykinins have utility in the following disorders: depression, dysthymic disorders, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina and Reynauld's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as systemic lupus erythmatosus (European patent specification no. 0 436 334), ophthalmic disease such as conjunctivitis, vernal conjunctivitis, and the like, and cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis (European patent specification no. 0 394 989).

International patent specification No. WO 93/14084, published 22nd July 1993 discloses piperidine tachykinin antagonists of the general formula



wherein

R¹ is optionally substituted phenyl;

R² is hydrogen, hydroxy or C₁₋₄alkoxy;

R³ is hydrogen or C₁₋₄alkyl;


5 R⁴ is hydrogen, C₁₋₄alkyl or C₁₋₄alkoxy;

R⁵ hydrogen, C₁₋₄alkyl, CF₃, CN or halogen; and

n is zero, 1 or 2.

10 In essence, the present invention provides a class of potent non-peptide tachykinin receptor antagonists. By virtue of their non-peptide nature, the compounds of the present invention do not suffer from the shortcomings, in terms of metabolic instability, of known peptide-based tachykinin receptor antagonists.

The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof:



15

wherein

Q represents a phenyl group substituted by one or more halo, optionally substituted naphthyl, optionally substituted indolyl, optionally substituted benzthiophenyl, optionally substituted benzofuranyl, 20 optionally substituted benzyl, or optionally substituted fluorenyl;

R¹ represents H, OH, C₁₋₆alkoxy or phenyloxy;

R² represents H, C₁₋₆alkyl or C₂₋₆alkenyl;

Z represents a group selected from

wherein

R^1 is optionally substituted phenyl;

R^2 is hydrogen, hydroxy or C_{1-4} alkoxy;

R^3 is hydrogen or C_{1-4} alkyl;


5 R^4 is hydrogen, C_{1-4} alkyl or C_{1-4} alkoxy;

R^5 hydrogen, C_{1-4} alkyl, CF_3 , CN or halogen; and

n is zero, 1 or 2.

In essence, the present invention provides a class of potent non-peptide tachykinin receptor antagonists. By virtue of their non-peptide
10 nature, the compounds of the present invention do not suffer from the shortcomings, in terms of metabolic instability, of known peptide-based tachykinin receptor antagonists.

The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof:



15


wherein

Q represents a phenyl group substituted by one or more halo, optionally substituted naphthyl, optionally substituted indolyl, optionally substituted benzthiophenyl, optionally substituted benzofuranyl,
20 optionally substituted benzyl, or optionally substituted fluorenyl;

R^1 represents H, OH, C_{1-6} alkoxy or phenyloxy;

R^2 represents H, C_{1-6} alkyl or C_{2-6} alkenyl;

Z represents a group selected from



where one of X and Y represents H and the other represents hydroxy or C₁₋₆alkoxy, or X and Y together form a group =O or =NOR⁵ where R⁵ is H or C₁₋₆alkyl;

5 R³ represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b independently represent H, C₁₋₆alkyl, phenyl or trifluoromethyl;

10 R⁴ represents H or C₁₋₆alkyl;

the dotted line represents an optional covalent bond;

Ar represents phenyl optionally substituted by 1 or 2 groups selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl; and

n represents 1 or 2.

15 As used herein, the definition of each expression, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.

The alkyl, alkenyl and alkynyl groups referred to with respect to any of the above formulae may represent straight or branched groups.

20 Thus, for example, suitable alkyl groups include methyl, ethyl, n- or isopropyl, n-, sec-, iso- or tert-butyl.

The cycloalkyl groups referred to with respect to any of the above definitions include cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

Similarly cycloalkyl-alkyl groups include cyclopropylmethyl.

25 Suitable alkenyl groups include vinyl and allyl; and suitable alkynyl groups include propargyl.

For the avoidance of doubt, when the covalent bond represented by the dotted line is present, the compounds of formula (I) contain an olefinic double bond.

The term "halo" as used herein includes fluoro, chloro, bromo and iodo, especially chloro and fluoro.

Where Q represents optionally substituted fluorenyl, the group is linked through the bridgehead carbon atom, that is to say, C-9 of the fluorenyl moiety.

Where Q represents optionally substituted naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or fluorenyl, suitable substituents include C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, SR^a, SOR^a, SO₂R^a, OR^a, NR^aR^b, NR^aCOR^b, NR^aCOOR^b, COOR^a or CONR^aR^b, where R^a and R^b are as above defined. One or more substituents may be present and each may be located at any available ring position, except, where Q is optionally substituted indolyl, the nitrogen atom. Where Q is optionally substituted indolyl, suitable nitrogen substituents include C₁₋₆alkyl, optionally substituted phenyl(C₁₋₆alkyl), COOR^a or CONR^aR^b, wherein R^a and R^b are as above defined.

Suitable values of the group Q include 3,4-dichlorophenyl, 3-indolyl, 2-naphthyl, 3-naphthyl, 9-fluorenyl, benzyl, 3-benzothiophenyl and 3-benzofuranyl.

Preferably Q is 3-indolyl, 3-benzothiophenyl or 3,4-dichlorophenyl, more preferably 3-indolyl.

Suitably R¹ represents OH or methoxy, preferably methoxy.

Preferably R² represents H or methyl, more preferably H.

Where Z represents a group of formula (a), preferably the double bond is absent.

Suitably one of X and Y represents hydroxy or C₁₋₆alkoxy, such as methoxy, or X and Y together represent =O or =NOH. Preferably one of X and Y represents methoxy or X and Y together represent =O. More preferably, X and Y together represent =O.

Where Z represents a group of formula (b), preferably R⁴ is H.

The term "halo" as used herein includes fluoro, chloro, bromo and iodo, especially chloro and fluoro.

Where Q represents optionally substituted fluorenyl, the group is linked through the bridgehead carbon atom, that is to say, C-9 of the fluorenyl moiety.

Where Q represents optionally substituted naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or fluorenyl, suitable substituents include C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, SR^a, SOR^a, SO₂R^a, OR^a, NR^aR^b, NR^aCOR^b, NR^aCOOR^b, COOR^a or CONR^aR^b, where R^a and R^b are as above defined. One or more substituents may be present and each may be located at any available ring position, except, where Q is optionally substituted indolyl, the nitrogen atom. Where Q is optionally substituted indolyl, suitable nitrogen substituents include C₁₋₆alkyl, optionally substituted phenyl(C₁₋₄alkyl), COOR^a or CONR^aR^b, wherein R^a and R^b are as above defined.

Suitable values of the group Q include 3,4-dichlorophenyl, 3-indolyl, 2-naphthyl, 3-naphthyl, 9-fluorenyl, benzyl, 3-benzothiophenyl and 3-benzofuranyl.

Preferably Q is 3-indolyl, 3-benzothiophenyl or 3,4-dichlorophenyl, more preferably 3-indolyl.

Suitably R¹ represents OH or methoxy, preferably methoxy.

Preferably R² represents H or methyl, more preferably H.

Where Z represents a group of formula (a), preferably the double bond is absent.

Suitably one of X and Y represents hydroxy or C₁₋₆alkoxy, such as methoxy, or X and Y together represent =O or =NOH. Preferably one of X and Y represents methoxy or X and Y together represent =O. More preferably, X and Y together represent =O.

Where Z represents a group of formula (b), preferably R⁴ is H.

Where Z represents either a group of formula (a) or a group of formula (b), preferably R^3 represents substituted phenyl. Suitable phenyl substituents include nitro, trifluoromethyl, trimethylsilyl, bromo, chloro, fluoro, iodo, cyano, methyl, ethyl, cyclopropyl, vinyl, methoxy, phenoxy and amino. Preferably R^3 represents disubstituted phenyl.

Particularly preferred are compounds wherein R^3 represents 3,5-bis(trifluoromethyl)phenyl.

When Ar represents substituted phenyl, the substituent(s) may be present at any available ring position, thus the substituent(s) may be present at the 2-, 3-, 4-, 5- and/or 6-position of the phenyl ring.


When Ar represents phenyl substituted by two substituents, the substituents may be the same or different.

Suitable substituents on the phenyl ring represented by Ar include, in particular, C_{1-4} alkyl, especially methyl, C_{1-4} alkoxy, especially methoxy, trifluoromethyl and halo, especially fluorine or chlorine.

Preferably Ar is unsubstituted phenyl, 4-methylphenyl, or 2-methylphenyl, especially unsubstituted phenyl.

In the compounds of formula (I), n may represent zero (i.e. a sulphide), 1 (i.e. a sulfoxide) or 2 (i.e. a sulphone). n is preferably zero or 1, and especially 1. When n is 1, the (R)-sulfoxide is most preferred.

A particular sub-group of compounds according to the invention is represented by compounds of formula (Ia), and pharmaceutically acceptable salts and prodrugs thereof:



(Ia)

wherein R^1 , R^2 , X, Y, Ar and n are as defined for formula (I);

the dotted line represents an optional covalent bond;


Z^1 represents O, S or NR^{14} (where R^{14} is H, C_{1-6} alkyl, optionally substituted phenyl(C_{1-4} alkyl), CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined), preferably S or NH;

R^{11} and R^{12} each independently represent H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined;

each R^{13} may occupy any available carbon atom of the bicyclic ring system and independently represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined; and

q is 0, 1, 2 or 3, preferably 0.

Another particular sub-group of compounds according to the invention is represented by compounds of formula (Ib), and pharmaceutically acceptable salts and prodrugs thereof:



(Ib)

wherein R^1 , Ar and n are as defined for formula (I);

Z^1 represents O, S or NR^{14} (where R^{14} is H, C_{1-6} alkyl, optionally substituted phenyl(C_{1-4} alkyl), CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined), preferably S or NH;

R^{11} and R^{12} each independently represent H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, chloro, bromo, fluoro, iodo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined;

each R^{13} may occupy any available carbon atom of the bicyclic ring system and independently represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined; and

q is 0, 1, 2 or 3, preferably 0.

For use in medicine, the salts of the compounds of formula (I) will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically

acceptable acid such as hydrochloric acid, sulphuric acid, oxalic acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Salts of amine groups may also comprise quaternary ammonium salts in which
5 the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Thus, for example, when R¹ or R⁵ is other than H, the nitrogen atom to which it is attached may be further substituted to give a quaternary ammonium salt. Furthermore, where the compounds of the invention carry an acidic moiety, suitable
10 pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be
15 functional derivatives of the compounds of formula (I) which are readily convertible *in vivo* into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in *Design of Prodrugs*, ed. H. Bundgaard, Elsevier, 1985.

20 The compounds according to the invention may exist both as enantiomers and as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

The invention also provides pharmaceutical compositions
25 comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier.

Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or
30 administration by inhalation or insufflation.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as

tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

Preferred compositions for administration by injection include those comprising a compound of formula (I), as the active ingredient, in association with a surface-active agent (or wetting agent or surfactant) or in the form of an emulsion (as a water-in-oil or oil-in-water emulsion).

Suitable surface-active agents include, in particular, non-ionic agents, such as polyoxyethylenesorbitans (e.g. Tween™ 20, 40, 60, 80 or 85) and other sorbitans (e.g. Span™ 20, 40, 60, 80 or 85). Compositions with a surface-active agent will conveniently comprise between 0.05 and 5% surface-active agent, and preferably between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.

Suitable emulsions may be prepared using commercially available fat emulsions, such as Intralipid™, Liposyn™, Infonutrol™, Lipofundin™ and Lipiphysan™. The active ingredient may be either dissolved in a pre-mixed emulsion composition or alternatively it may be dissolved in an oil (e.g. soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid (e.g. egg phospholipids, soybean phospholipids or soybean lecithin) and water. It will be appreciated that other ingredients may be added, for example glycerol or glucose, to adjust the tonicity of the emulsion. Suitable emulsions will typically contain up to 20% oil, for example, between 5 and 20%. The fat emulsion will preferably comprise fat droplets between 0.1 and 1.0µm, particularly 0.1 and 0.5µm, and have a pH in the range of 5.5 to 8.0.

Particularly preferred emulsion compositions are those prepared by mixing a compound of formula (I) with Intralipid™ or the components thereof (soybean oil, egg phospholipids, glycerol and water).

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents,

or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably
5 sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be administered, preferably orally
10 or nasally, from devices which deliver the formulation in an appropriate manner.

The present invention further provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), which process comprises bringing a compound of formula (I)
15 into association with a pharmaceutically acceptable carrier or excipient.

The compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions which are characterised by the presence of an excess of tachykinin, in particular substance P, activity. These may include disorders of the central nervous system such as anxiety,
20 depression, psychosis and schizophrenia; epilepsy; neurodegenerative disorders such as dementia, including AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) and other
25 neuropathological disorders such as peripheral neuropathy, for example AIDS related neuropathy, diabetic and chemotherapy-induced neuropathy, and postherpetic and other neuralgias; neuronal damage, such as cerebral ischemic damage and cerebral edema in cerebrovascular disorders; small cell carcinomas such as small cell lung cancer; respiratory
30 diseases, particularly those associated with excess mucus secretion such as chronic obstructive airways disease, bronchopneumonia, chronic

bronchitis, asthma, and bronchospasm; airways diseases modulated by neurogenic inflammation; diseases characterised by neurogenic mucus secretion, such as cystic fibrosis; diseases associated with decreased glandular secretions, including lacrimation, such as Sjogren's syndrome, hyperlipoproteinemias IV and V, hemochromatosis, sarcoidosis, and amyloidosis; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, ocular inflammation, osteoarthritis, rheumatoid arthritis, pruritis and sunburn; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, dry eye syndrome, and the like; ophthalmic conditions associated with cell proliferation such as proliferative vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis; addiction disorders including the withdrawal response produced by chronic treatment with, or abuse of, drugs such as benzodiazepines, opiates, cocaine, alcohol and nicotine; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; gastrointestinal (GI) disorders, including inflammatory disorders and diseases of the GI tract such as gastritis, gastroduodenal ulcers, gastric carcinomas, gastric lymphomas, disorders associated with the neuronal control of viscera, ulcerative colitis, Crohn's disease, irritable bowel syndrome and emesis, including acute, delayed, post-operative, late phase or anticipatory emesis such as emesis induced by chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, motion, surgery, migraine, opioid analgesics, and variations in intracranial pressure, in particular, for example, drug or radiation induced emesis or post-operative nausea and vomiting; disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia and incontinence; fibrosing and collagen

diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, for example, that attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.

The compounds of formula (I) are also of value in the treatment of a combination of the above conditions, in particular in the treatment of

combined post-operative pain and post-operative nausea and vomiting.

The compounds of formula (I) are particularly useful in the treatment of emesis, including acute, delayed or anticipatory emesis, such as emesis induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders including motion sickness, surgery, migraine, and variations in intracranial pressure. Most especially, the compounds of formula (I) are of use in the treatment of emesis induced by antineoplastic (cytotoxic) agents including those routinely used in cancer chemotherapy.

Examples of such chemotherapeutic agents include alkylating agents, for example, nitrogen mustards, ethyleneimine compounds, alkyl sulphonates and other compounds with an alkylating action such as nitrosoureas, cisplatin and dacarbazine; antimetabolites, for example, folic acid, purine or pyrimidine antagonists; mitotic inhibitors, for example, vinca alkaloids and derivatives of podophyllotoxin; and cytotoxic antibiotics.

Particular examples of chemotherapeutic agents are described, for instance, by D. J. Stewart in *Nausea and Vomiting: Recent Research and Clinical Advances*, Eds. J. Kuucharczyk et al, CRC Press Inc., Boca Raton, Florida, USA (1991) pages 177-203, especially page 188. Commonly used chemotherapeutic agents include cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin

and chlorambucil [R. J. Gralla *et al* in *Cancer Treatment Reports* (1984) 68(1), 163-172].

5 The compounds of formula (I) are also of use in the treatment of emesis induced by radiation including radiation therapy such as in the treatment of cancer, or radiation sickness; and in the treatment of post-operative nausea and vomiting.

10 It will be appreciated that the compounds of formula (I) may be presented together with another therapeutic agent as a combined preparation for simultaneous, separate or sequential use for the relief of emesis. Such combined preparations may be, for example, in the form of a twin pack. A preferred combination comprises the compounds of formula (I) with a chemotherapeutic agent such as an alkylating agent, antimetabolite, mitotic inhibitor or cytotoxic antibiotic, as described above. In general, the currently available dosage forms of the known therapeutic agents for use in such combinations will be suitable.

15 The compounds of formula (I) are also particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteoarthritis, rheumatoid arthritis and especially migraine.

The present invention further provides a compound of formula (I) for use in therapy.

25 According to a further or alternative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment of physiological disorders associated with an excess of tachykinins, especially substance P.

30 The present invention also provides a method for the the treatment or prevention of physiological disorders associated with an excess of tachykinins, especially substance P, which method comprises administration to a patient in need thereof of a tachykinin reducing

amount of a compound of formula (I) or a composition comprising a compound of formula (I).

For the treatment of certain conditions it may be desirable to employ a compound according to the present invention in conjunction with another pharmacologically active agent. For example, for the treatment of respiratory diseases such as asthma, a compound of formula (I) may be used in conjunction with a bronchodilator, such as a β 2-adrenergic receptor antagonist or tachykinin antagonist which acts at NK-2 receptors. The compound of formula (I) and the bronchodilator may be administered to a patient simultaneously, sequentially or in combination.

Likewise, a compound of the present invention may be employed with a leukotriene antagonists, such as a leukotriene D₄ antagonist such as a compound selected from those disclosed in European patent specification nos. 0 480 717 and 0 604 114 and in US patent nos. 4,859,692 and 5,270,324. This combination is particularly useful in the treatment of respiratory diseases such as asthma, chronic bronchitis and cough.

The present invention accordingly provides a method for the treatment of a respiratory disease, such as asthma, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) and an effective amount of a bronchodilator.

The present invention also provides a composition comprising a compound of formula (I), a bronchodilator, and a pharmaceutically acceptable carrier.

It will be appreciated that for the treatment or prevention of migraine, a compound of the present invention may be used in conjunction with other anti-migraine agents, such as ergotamines or 5-HT₁ agonists, especially sumatriptan.

Likewise, for the treatment of behavioural hyperalgesia, a compound of the present invention may be used in conjunction with an antagonist of N-methyl D-aspartate (NMDA), such as dizocilpine.

For the treatment or prevention of inflammatory conditions in the lower urinary tract, especially cystitis, a compound of the present invention may be used in conjunction with an antiinflammatory agent such as a bradykinin receptor antagonist.

In the treatment of the conditions associated with an excess of tachykinins, a suitable dosage level is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg per day.


For example, in the treatment of conditions involving the neurotransmission of pain sensations, a suitable dosage level is about 0.001 to 25 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

In the treatment of emesis using an injectable formulation, a suitable dosage level is about 0.001 to 10 mg/kg per day, preferably about 0.005 to 5 mg/kg per day, and especially 0.01 to 1 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

It will be appreciated that the amount of a compound of formula (I) required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.

Compounds of formula (I) may be prepared from intermediates of formula (II):

- 19 -




(II)


wherein Q, R², and Z are as defined for formula (I), by reaction with CH₃S(O)_nAr, where Ar and n are as defined for formula (I), after deprotonation with a strong base such as lithium hexamethyldisilylamide,
 5 lithium bis(trimethylsilyl)amide or lithium diisopropylamide.

The reaction is conveniently effected in a suitable solvent such as, an ether, for example, tetrahydrofuran, at a temperature between -78°C and 30°C, for example, -70°C.

Intermediates of formula (II) may be prepared by reaction of a
 10 simple alkyl quaternary salt of 4-oxo-piperidine, especially 1,1-dimethyl-4-oxopiperidinium iodide, with a compound of formula (IIIA) or (IIIB):



(IIIA)




(IIIB)

wherein Q, R², R³, R⁴, X, Y, Z and the dotted line are as defined for formula (I), in the presence of a base.

15 Suitable bases include alkali metal carbonates, such as, for example, potassium carbonate.

The reaction is conveniently effected in a suitable organic solvent, such as an alcohol, e.g. ethanol, suitably at elevated temperature.

Compounds of formula (IIIA), in which X and Y together represent
 20 =O and the double bond is present, may be prepared by the reaction of an aldehyde of formula R³CHO with a compound of formula (IV)



(IV)

wherein Q and R² are as defined for formula (I), R²⁰ represents a group PR^x₃ or PO(OR^x)₂, wherein R^x represents phenyl or C₁₋₁₀alkyl, and R³⁰ represents a suitable amine protecting group such as an
5 aralkyloxycarbonyl group, especially benzyloxycarbonyl, or an alkoxy carbonyl group, especially *tert*-butoxycarbonyl (*t*-BOC), in the presence of a base.

a C₁₋₈alkylhalide. Suitable halides include, in particular, bromides and iodides.

The reaction is conveniently effected in an anhydrous organic solvent, for example, an ether, e.g. dimethoxyethane, suitably at ambient temperature.


Compounds of formula (IIIA) wherein X and Y together represent =NOR^s may be prepared from the corresponding compounds of formula (IIIA) wherein X and Y together represent =O by the addition of hydroxylamine, or a derivative thereof. Compounds wherein R^s is other than H may be prepared from the corresponding compounds wherein R^s is H by alkylation, for example, using a diazo compound, such as diazomethane, or an alkyl halide or sulphate.

Compounds of formula (IIIA) wherein the double bond is absent may be prepared from the corresponding unsaturated compounds of formula (IIIA) by reduction.

Suitable reduction procedures include catalytic hydrogenation. Suitable hydrogenation catalysts include noble metals, for example, platinum or palladium, or oxides thereof, which may be supported, for example, on charcoal. A preferred catalyst is Wilkinson's catalyst (tris(triphenylphosphine)rhodium(I)chloride).

The reaction is conveniently effected in a suitable organic solvent, such as an ether, e.g. tetrahydrofuran, an alcohol, e.g. ethanol, or an ester, e.g. ethyl acetate, suitably at ambient temperature.

Compounds of formula (IIIB) may be prepared by reaction of a compound of formula (V):




(V)

wherein Q and R² are as defined for formula (I) and R³⁰ is a protecting group as previously defined, with an amine of formula HNR⁴-CH₂R³, wherein R³ and R⁴ are as defined for formula (I).

The reaction is suitably effected in the presence of a base, such as a tertiary amine, for example, triethylamine, preferably in the presence of a suitable alkylchloroformate, such as t-butylchloroformate, conveniently in a suitable organic solvent, such as a halogenated hydrocarbon, e.g. dichloromethane. Alternatively, the reaction may be effected in the presence of a coupling agent, such as dicyclohexylcarbodiimide.

Compounds of formula (V) are commercially available or may be prepared using standard syntheses. Syntheses of amino acids are well documented and are described, for example, in *Chemistry and Biochemistry of the Amino Acids*, ed. G. C. Barrett, Chapman and Hall, 1985.

Compounds of formula (IV) may be prepared from compounds of formula (VI)




wherein Q and R² are as defined for formula (I), R³⁰ is a protecting group as previously defined and R²¹ represents an alkoxy or a suitably substituted amino group, such as a group NR^yOR^z, where R^y and R^z represent alkyl, in particular a group NCH₃(OCH₃), by reaction with a compound of formula CH₃PO(OR^x)₂, where R^x is an alkyl group, in the presence of a base.

Suitable reaction procedures will be readily apparent to the skilled person.

Suitable bases of use in the reaction include alkyl lithiums, such as butyl lithium.

Compounds of formula (VI) are commercially available or may be prepared using standard procedures well known to the skilled person in the art. The compounds of formula (VI) are amino acid derivatives. Syntheses of amino acids and derivatives thereof are well documented and
5 are described, for example, in *Chemistry and Biochemistry of the Amino Acids*, ed. G. C. Barrett, Chapman and Hall, 1985.

A particularly convenient synthesis of compounds of formula (I) wherein Z represents a group of formula (a), involving the necessary steps of protection and deprotection, is illustrated by the following scheme:



Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated, suitably by conventional techniques such as preparative chromatography.


5 The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an
10 optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

15 During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and
20 P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

 The compounds of this invention may be formulated as specifically illustrated at pages 28 to 29 of European Patent Specification No.
25 EP-A-0 528 495.

CLAIMS:

1. A compound of the formula (I), or a pharmaceutically acceptable salt or prodrug thereof:




wherein

Q represents a phenyl group substituted by one or more halo, optionally substituted naphthyl, optionally substituted indolyl, optionally substituted benzthiophenyl, optionally substituted benzofuranyl, optionally substituted benzyl, or optionally substituted fluorenyl;

R¹ represents H, OH, C₁₋₆alkoxy or phenyloxy;

R² represents H, C₁₋₆alkyl or C₂₋₆alkenyl;

Z represents a group selected from



where one of X and Y represents H and the other represents hydroxy or C₁₋₆alkoxy, or X and Y together form a group =O or =NOR⁵ where R⁵ is H or C₁₋₆alkyl;

R³ represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl,

C₃₋₇cycloalkylC₁₋₄alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b independently represent H, C₁₋₆alkyl, phenyl or trifluoromethyl;


R⁴ represents H or C₁₋₆alkyl;

the dotted line represents an optional covalent bond;

Ar represents phenyl optionally substituted by 1 or 2 groups selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl; and

n represents 1 or 2.

2. A compound as claimed in claim 1 of formula (Ia), or a pharmaceutically acceptable salt or prodrug thereof:



(Ia)

wherein R¹, R², X, Y, Ar and n are as defined in claim 1;

the dotted line represents an optional covalent bond;


Z¹ represents O, S or NR¹⁴ (where R¹⁴ is H, C₁₋₆alkyl, optionally substituted phenyl(C₁₋₄alkyl), CO₂R^a or CONR^aR^b, where R^a and R^b are as defined in claim 1);

R^{11} and R^{12} each independently represent H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are as defined in claim 1;

each R¹³ may occupy any available carbon atom of the bicyclic ring system and independently represents C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b are as defined in claim 1; and

q is 0, 1, 2 or 3.

3. A compound as claimed in claim 1 of the formula (Ib), or a pharmaceutically acceptable salt or prodrug thereof:



(Ib)

wherein R¹, Ar and n are as defined in claim 1;

Z¹ represents O, S or NR¹⁴ (where R¹⁴ is H, C₁₋₆alkyl, optionally substituted phenyl(C₁₋₄alkyl), CO₂R^a or CONR^aR^b, where R^a and R^b are as defined in claim 1);

R¹¹ and R¹² each independently represent H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, chloro, bromo, fluoro, iodo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b are as defined in claim 1;

each R¹³ may occupy any available carbon atom of the bicyclic ring system and independently represents C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b are as defined in claim 1; and

q is 0, 1, 2 or 3.

4. A compound as claimed in claim 1 wherein Q is 3-indolyl, 3-benzothiophenyl or 3,4-dichlorophenyl.

5. A compound as claimed in claim 2 or claim 3 wherein Z^1 represents S or NH.

5 6. A compound as claimed in any one of claims 1 to 5 wherein R^1 represents OH or methoxy.

7. A compound as claimed in claim 1 or claim 2 wherein R^2 represents H or methyl.

10

8. A compound as claimed in claim 1 or claim 2 wherein the double bond is absent.

9. A compound as claimed in claim 1 or claim 2 wherein one of
15 X and Y represents methoxy or X and Y together represent =O.

10. A compound as claimed in claim 1 or claim 3 wherein R^4 represents a hydrogen atom.

20

11. A compound as claimed in claim 1 wherein R^3 represents disubstituted phenyl.

12. A compound as claimed in claim 11 wherein R^3 represents 3,5-bis(trifluoromethyl)phenyl.

25

13. A compound as claimed in any one of claims 1 to 12 wherein Ar represents unsubstituted phenyl, 4-methylphenyl, or 2-methylphenyl.

14. A compound as claimed in any one of claims 1 to 13 wherein
30 n is zero or 1.

15. A compound as claimed in any preceding claim for use in therapy.

5 16. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 14 in association with a pharmaceutically acceptable carrier or excipient.

10 17. The use of a compound as claimed in any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of a physiological disorder associated with an excess of tachykinins.

18. The use of a compound as claimed in any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of pain or inflammation.


15 19. The use of a compound as claimed in any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of migraine.

20 20. The use of a compound as claimed in any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of emesis.

25 21. The use of a compound as claimed in any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of postherpetic neuralgia.

22. A process for the preparation of a compound of formula (I) as claimed in claim 1, which comprises:

30 (A) reacting a compound of formula (II):



(II)

wherein Q, R², and Z are as defined in claim 1, with CH₃S(O)_nAr, where Ar and n are as defined in claim 1;

each process being followed, where necessary, by the removal of any
5 protecting group where present;

and when the compound of formula (I) is obtained as a mixture of enantiomers or diastereoisomers, optionally resolving the mixture to obtain the desired enantiomer;

and/or, if desired, converting the resulting compound of formula (I)
10 or a salt thereof, into a pharmaceutically acceptable salt or prodrug thereof.

Patents Act 1977
aminer's report to the Comptroller under Section 17
(The Search report)

32

Application number
 GB 9515775.6

Relevant Technical Fields

- (i) UK Cl (Ed.N) C2C (CQN CQT CRE)
 (ii) Int Cl (Ed.6) C07D

Search Examiner
 D S LUCAS

Date of completion of Search
 10 OCTOBER 1995

Databases (see below)

(i) UK Patent Office collections of GB, EP, WO and US patent specifications.

(ii) ONLINE: CAS ONLINE

Documents considered relevant
 following a search in respect of
 Claims :-
 1-22

Categories of documents

- | | |
|--|--|
| <p>: Document indicating lack of novelty or of inventive step.</p> <p>: Document indicating lack of inventive step if combined with one or more other documents of the same category.</p> <p>: Document indicating technological background and/or state of the art.</p> | <p>P: Document published on or after the declared priority date but before the filing date of the present application.</p> <p>E: Patent document published on or after, but with priority date earlier than, the filing date of the present application.</p> <p>&: Member of the same patent family; corresponding document.</p> |
|--|--|

Category	Identity of document and relevant passages	Relevant to claim(s)
A	WO 93/14084 A (GLAXO) see particularly Claim 1	1-22

Databases: The UK Patent Office database comprises classified collections of GB, EP, WO and US patent specifications as outlined periodically in the Official Journal (Patents). The on-line databases considered for search are also listed periodically in the Official Journal (Patents).